Article Details

Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in ...

Retrieved on: 2020-12-18 21:56:15

Tags for this article:

Click the tags to see associated articles and topics

Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in .... View article details on hiswai:

Excerpt

<b>Monoclonal antibodies</b>, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients requiring ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up